Davar, D., Williams, A., Lopez, J., Olson, D., Sato, T., Shaw, H., Friedman, C. F., Thistlethwaite, F., Middleton, M., Lebbe, C., Ma, V. T., Izar, B., Lau, P., Bechter, O., Kirk, P., Yuan, Y., Marshall, S., & Hamid, O. (2024). 694 Phase 1 safety and efficacy of brenetafusp, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM). Regular and Young Investigator Award Abstracts, A796–A796. https://doi.org/10.1136/jitc-2024-sitc2024.0694